Clozapine-resistant schizophrenia (CRS) occurs in 40%-70% of clozapine-treated schizophrenic patients. Hereby we describe a 20-year-old CRS subject with comorbid cannabinoid use disorder, successfully treated with clozapine-brexpiprazole combination, subsequently switched to clozapine plus long-acting injectable aripiprazole.
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy / Orsolini, Laura; Bellagamba, Silvia; Salvi, Virginio; Volpe, Umberto. - In: ASIAN JOURNAL OF PSYCHIATRY. - ISSN 1876-2018. - 72:(2022), p. 103121. [10.1016/j.ajp.2022.103121]
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy
Orsolini, Laura;Bellagamba, Silvia;Salvi, Virginio;Volpe, Umberto
2022-01-01
Abstract
Clozapine-resistant schizophrenia (CRS) occurs in 40%-70% of clozapine-treated schizophrenic patients. Hereby we describe a 20-year-old CRS subject with comorbid cannabinoid use disorder, successfully treated with clozapine-brexpiprazole combination, subsequently switched to clozapine plus long-acting injectable aripiprazole.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
